HCWB HCW Biologics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1828673 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,487.6%
TTM net income YoY64.7%
TTM EPS YoY162.3%
Revenue 3-yr CAGR32.8%
Net income 3-yr CAGR—
Margins
Gross margin96.6%
Operating margin-104.2%
Net margin-63.4%
FCF margin—
EBITDA margin-96.1%
Returns
ROE-180.3%
ROA-16.8%
ROIC (approx.)-116.5%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets72.8%
Debt / equity0.00x
Current ratio0.07x
Interest coverage-12.39x
Cash quality & payout
Operating cash flow / net income2.71x
Accruals ratio28.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $54,232 | $2.57M |
| Cost of revenue | $43,386 | $1.61M |
| Gross profit | $10,846 | $959,403 |
| R&D expense | $5.44M | $6.39M |
| SG&A expense | $7.70M | $6.82M |
| Operating income | -$13.16M | -$29.46M |
| Interest expense | $845,051 | $654,284 |
| Pretax income | -$7.96M | -$30.02M |
| Income tax | $0 | $0 |
| Net income | -$7.96M | -$30.02M |
| EBITDA | -$12.12M | -$28.27M |
| EPS (basic) | -10.63 | -30.96 |
| EPS (diluted) | -10.63 | -30.96 |
| Weighted avg. shares (diluted) | 2.10M | 969,825 |
| Balance sheet | ||
| Cash & equivalents | $1.95M | $4.67M |
| Short-term investments | $0 | $0 |
| Receivables | $32,175 | $582,201 |
| Current assets | $2.28M | $5.70M |
| PP&E, net | $20.88M | $22.91M |
| Total assets | $24.52M | $30.24M |
| Current liabilities | $21.06M | $29.63M |
| Short-term debt | $6.81M | $6.31M |
| Long-term debt | $0 | $7.38M |
| Total debt | $6.81M | $13.69M |
| Total liabilities | $21.76M | $37.01M |
| Shareholders' equity | $2.76M | -$6.77M |
| Net debt | $4.86M | $9.02M |
| Cash flow statement | ||
| Operating cash flow | -$13.39M | -$14.23M |
| Capital expenditure | $0 | $261,617 |
| Free cash flow | -$13.39M | -$14.49M |
| Investing cash flow | $0 | -$261,617 |
| Financing cash flow | $10.67M | $15.57M |
| Depreciation & amortization | $1.04M | $1.18M |
| Stock-based compensation | $768,623 | $1.01M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.